Despite the large number of GR-binding sites on the genome, only a small number of genes were deregulated in response to Dex (982 up-regulated, 3.2%; 649 down-regulated, 2.1%; abs [log2fold change] > 0.6 and FDR < 0.05) in myeloma cells including well-known ubiquitous GR-responsive genes like TSC22D3 (alias GILZ), FKBP5, and cell-specific genes like BCL2L11 (alias BIM), an essential gene for Dex-induced death in MM.1S, and CXCR4, the chemokine receptor gene known to be associated with MM progression and poor prognosis (Fig 1F). This evidence concerns the gene BCL2L11 and Miyoshi myopathy.